Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma.
Blood. 2022 Apr 21;139(16):2471-2482. doi: 10.1182/blood.2021015161.
Blood. 2022.
PMID: 35134130
Free article.